Alessandro M Vannucchi

Alessandro M Vannucchi

UNVERIFIED PROFILE

Are you Alessandro M Vannucchi?   Register this Author

Register author
Alessandro M Vannucchi

Alessandro M Vannucchi

Publications by authors named "Alessandro M Vannucchi"

Are you Alessandro M Vannucchi?   Register this Author

100Publications

3328Reads

37Profile Views

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis.

Am J Hematol 2019 Aug 21;94(8):845-852. Epub 2019 May 21.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Denothe Excellence Center, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25506DOI Listing
August 2019

Spectrum of mutations in primary myelofibrosis: prognostic impact of the p.G646Wfs*12 mutation.

Blood 2019 Jun 10;133(26):2802-2808. Epub 2019 May 10.

Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Dipartimento di Medicina Sperimentale e Clinica, Azienda Ospedaliera Universitaria Careggi, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2018879536DOI Listing
June 2019

The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all.

Am J Hematol 2019 Mar 18;94(3):283-285. Epub 2018 Dec 18.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Firenze, and DENOTHE Excellence Center, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25367DOI Listing
March 2019

Validation of the Mayo alliance prognostic system for mastocytosis.

Blood Cancer J 2019 02 11;9(2):18. Epub 2019 Feb 11.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0179-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370807PMC
February 2019

A case of disseminated blastic plasmocytoid dendritic cell neoplasm.

Am J Hematol 2018 11 24;93(11):1433-1434. Epub 2018 Jul 24.

Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25109DOI Listing
November 2018

Prefibrotic myelofibrosis: treatment algorithm 2018.

Blood Cancer J 2018 11 7;8(11):104. Epub 2018 Nov 7.

FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0142-z
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0142-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221891PMC
November 2018

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.

Blood Cancer J 2018 11 7;8(11):103. Epub 2018 Nov 7.

Fondazione Policlinico Universitario A. Gemelli IRCCS, and Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0143-y
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0143-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221886PMC
November 2018

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Blood Cancer J 2018 11 22;8(12):122. Epub 2018 Nov 22.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0152-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250726PMC
November 2018

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Blood Cancer J 2018 11 26;8(12):124. Epub 2018 Nov 26.

Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative neoplasms (CRIMM), AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0161-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255832PMC
November 2018

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

N Engl J Med 2018 10;379(15):1416-1430

From the Wellcome-MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research (J.G., C.E.M., F.L.N., A.R.G., P.J.C.), the Department of Haematology, University of Cambridge (J.G., E.J.B., C.M., J.C., C.E.M., F.L.N., A.R.G.), and the Department of Haematology, Cambridge University Hospitals NHS Foundation Trust (J.G., E.J.B., A.L.G., C.M., J.C., A.R.G.), Cambridge, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (J.N., D.C.W., N.A., E.P., G.G., L.O., S.O., J.W.T., A.P.B., N.W., P.J.C.), and the European Molecular Biology Laboratory, European Bioinformatics Institute (R.C., M.G.), Hinxton, Big Data Institute, University of Oxford, Oxford (D.C.W.), the Department of Haematology, Queen's University Belfast, Belfast (M.F.M.), and the Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.) - all in the United Kingdom; the Center for Molecular Oncology and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York (E.P., G.G.); the Department of Hematology, Zealand University Hospital, Roskilde, and the University of Copenhagen, Copenhagen (C.L.A., H.C.H.); and the Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy (P.G., A.M.V.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716614
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716614DOI Listing
October 2018

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Leukemia 2018 09 28;32(9):2077-2081. Epub 2018 Jun 28.

Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0199-5DOI Listing
September 2018

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.

Am J Hematol 2018 08;93(4):E93-E96

Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25017
Publisher Site
http://dx.doi.org/10.1002/ajh.25017DOI Listing
August 2018

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Leukemia 2018 07 23;32(7):1631-1642. Epub 2018 Mar 23.

Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0107-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035151PMC
July 2018

Myelofibrosis Treatment Algorithm 2018.

Blood Cancer J 2018 07 31;8(8):72. Epub 2018 Jul 31.

Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0109-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068139PMC
July 2018

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

J Clin Oncol 2018 06 30;36(17):1769-1770. Epub 2018 Apr 30.

Ayalew Tefferi, Mayo Clinic, Rochester, MN; Paola Guglielmelli, University of Florence, Florence, Italy; Terra L. Lasho, Naseema Gangat, Rhett P. Ketterling, and Animesh Pardanani, Mayo Clinic, Rochester, MN; and Alessandro M. Vannucchi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9867DOI Listing
June 2018

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Am J Hematol 2018 03 18;93(3):348-355. Epub 2017 Dec 18.

Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24978DOI Listing
March 2018

Polycythemia vera and essential thrombocythemia: algorithmic approach.

Curr Opin Hematol 2018 03;25(2):112-119

Department of Internal Medicine, Divisions of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000402DOI Listing
March 2018

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

J Clin Oncol 2018 02 9;36(4):310-318. Epub 2017 Dec 9.

Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Annalisa Pacilli, Francesco Mannelli, and Alessandro M. Vannucchi, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence; Elisa Rumi, Vittorio Rosti, Giovanni Barosi, and Mario Cazzola, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Elisa Rumi and Mario Cazzola, University of Pavia, Pavia; Alessandro Rambaldi, University of Milan, Milan; Alessandro Rambaldi and Tiziano Barbui, Azienda Socio sanitaria Territoriale Papa Giovanni XXIII, Bergamo; Francesco Passamonti, University of Insubria, Varese, Italy; and Terra L. Lasho, Mythri Mudireddy, Maura Nicolosi, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, and Ayalew Tefferi, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4886DOI Listing
February 2018

Essential thrombocythemia treatment algorithm 2018.

Blood Cancer J 2018 01 10;8(1). Epub 2018 Jan 10.

Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-017-0041-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802626PMC
January 2018

Polycythemia vera treatment algorithm 2018.

Blood Cancer J 2018 01 10;8(1). Epub 2018 Jan 10.

Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-017-0042-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802495PMC
January 2018

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):480-488

Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Careggi University Hospital/University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142598PMC
December 2017

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

Stem Cells Dev 2017 Dec 19. Epub 2017 Dec 19.

Universita degli Studi di Modena e Reggio Emilia Dipartimento di Scienze della Vita, 117706, Centre for Regenerative Medicine, Department of Life Sciences , VIA CAMPI 287 , Modena, Italy , 41100 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/scd.2017.0137DOI Listing
December 2017

Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.

Am J Hematol 2017 Nov 28;92(11):1193-1197. Epub 2017 Aug 28.

Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24882DOI Listing
November 2017

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in mutated cells through PP2A/CIP2A axis.

Oncotarget 2017 Nov 22;8(57):96710-96724. Epub 2017 May 22.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722516PMC
November 2017

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Leuk Res 2017 10 10;61:6-9. Epub 2017 Aug 10.

Department of Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.08.002DOI Listing
October 2017

Traffic lights for ruxolitinib.

Blood 2017 08;130(9):1075-1077

UNIVERSITY OF FLORENCE.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-07
Publisher Site
http://dx.doi.org/10.1182/blood-2017-07-795880DOI Listing
August 2017

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Eur J Haematol 2017 Jul 5;99(1):36-41. Epub 2017 May 5.

Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12887DOI Listing
July 2017

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.

Leuk Res 2017 07 23;58:63-72. Epub 2017 Apr 23.

Center for the Study of Myelofibrosis, Biotechnology Research Area, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.04.006DOI Listing
July 2017

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Haematologica 2017 06 2;102(6):e219-e221. Epub 2017 Mar 2.

Department of Experimental and Clinical Medicine, CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproloiferative, Azienda ospedaliera-Universitaria Careggi, University of Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.165126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451347PMC
June 2017

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Leuk Res 2017 05 31;56:52-59. Epub 2017 Jan 31.

CRIMM-Center of Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi and University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.01.032DOI Listing
May 2017

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Am J Hematol 2017 05 4;92(5):417-419. Epub 2017 Mar 4.

Hematology division, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24684DOI Listing
May 2017

Managing patients with myelofibrosis and low platelet counts.

Ann Hematol 2017 Apr 21;96(4):537-548. Epub 2016 May 21.

CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2697-8DOI Listing
April 2017

Emerging treatments for classical myeloproliferative neoplasms.

Blood 2017 02 27;129(6):693-703. Epub 2016 Dec 27.

Department of Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-695965DOI Listing
February 2017

Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.

Ann Hematol 2017 Jan 13;96(1):87-92. Epub 2016 Oct 13.

Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2826-4DOI Listing
January 2017

From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Haematologica 2017 01 24;102(1):18-29. Epub 2016 Nov 24.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, DENOTHE Excellence Center, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.129155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210229PMC
January 2017

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Blood Adv 2016 Nov 22;1(1):21-30. Epub 2016 Nov 22.

Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and.

View Article

Download full-text PDF

Source
http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvance
Publisher Site
http://dx.doi.org/10.1182/bloodadvances.2016000216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744051PMC
November 2016

The prognostic impact of bone marrow fibrosis in primary myelofibrosis.

Am J Hematol 2016 Oct 29;91(10):E454-5. Epub 2016 Jul 29.

CRIMM-Centro Ricerca E Innovazione Delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24482DOI Listing
October 2016

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Am J Hematol 2016 09 4;91(9):918-22. Epub 2016 Jul 4.

Department of Experimental and Clinical Medicine and DENOTHE Excellence Center, CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24442DOI Listing
September 2016

Improving prognostic tools in systemic mastocytosis: Insights from mutations.

Am J Hematol 2016 09 4;91(9):867-8. Epub 2016 Aug 4.

CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24472DOI Listing
September 2016

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Br J Haematol 2016 06 25;173(6):938-40. Epub 2015 Aug 25.

Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13644DOI Listing
June 2016

Myeloproliferative neoplasms: Morphology and clinical practice.

Am J Hematol 2016 Jun;91(4):430-3

Hematology division, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24288DOI Listing
June 2016

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

J Clin Oncol 2016 Jan 23;34(2):151-9. Epub 2015 Nov 23.

Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, and Ruben A. Mesa, Mayo Clinic, Scottsdale, AZ; Jean-Jacques Kiladjian, Hospital Saint-Louis, Paris; Francoise Boyer, Centre Hospitalier Universitaire, Angers; Gabriel Etienne, Institut Bergonie, Bordeaux; Jean-Christophe Ianotto, Centre Hospitalier Universitaire, Brest; Dana Ranta, Centre Hospitalier Universitaire, Grenoble; Lydia Roy, Centre Hospitalier Universitaire, Poitiers; Jean-Yves Cahn, Centre Hospitalier Universitaire, Grenoble, France; Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, and Peihong Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Stefanie Slot and Sonja Zweegman, VU University Medical Center, Amsterdam; Peter A.W. te Boekhorst, Erasmus Medical Center, Rotterdam; Suzan Commandeur, Leiden University Medical Center, Leiden; Harry Schouten, Maastricht University Medical Center, Maastricht, the Netherlands; Frederico Sackmann, Fundaleu, Buenos Aires, Argentina; Ana Kerguelen Fuentes and Dolores Hernández-Maraver, University Hospital La Paz, Madrid; Carlos Besses, Hospital del Mar; Francisco Cervantes, University of Barcelona, Barcelona, Spain; Konstanze Döhner and Frank Stegelmann, University Hospital of Ulm; Karin Bonatz and Andreas Reiter, Universitätsmedizin Mannheim, Mannheim; Heike L. Pahl, University Hospital Freiburg, Freiburg; Martin Griesshammer, Johannes Wesling Klinikum Minden, Germany; Claire N. Harrison and Deepti Radia, Guy's and St Thomas NHS Foundation Trust; Robert Peter Gale, Imperial College, London, United Kingdom; Pablo Muxi, Hospital Británico, Montevideo, Uruguay; Peter L. Johansson and Bjorn Andreasson, NU Hospital Organization, Uddevalla; Gunnar Birgegard, University Hospital, Uppsala; Jan Samuelsson, Stockholm South Hospital, Stockholm, Sweden; Alessandro Rambaldi, Tiziano Barbui, and Maria L. Ferrari, Ospedali Riuniti di Bergamo, Bergamo; Giovanni Barosi, IRCCS Policlinico S. Matteo Foundation; Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.9337DOI Listing
January 2016

STAT1 activation in association with JAK2 exon 12 mutations.

Haematologica 2016 Jan 3;101(1):e15-9. Epub 2015 Dec 3.

Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, UK Department of Haematology, Addenbrooke's Hospital, UK Department of Haematology, University of Cambridge, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.128546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697901PMC
January 2016

Closing the gap: genetic landscape of MPN.

Blood 2016 Jan;127(3):276-8

UNIVERSITY OF FLORENCE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-674101DOI Listing
January 2016

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Haematologica 2015 Jun 3;100(6):757-67. Epub 2015 Apr 3.

INSERM UMR-S1197, Paul Brousse Hospital, Paris-Sud University, Villejuif, France INSERM UMS33, Paul Brousse Hospital, Paris-Sud University, Villejuif, France French Intergroup on Myeloproliferative Neoplasms (FIM), France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450621PMC
June 2015

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Blood 2015 May;125(21):3352-3

Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-01-62
Publisher Site
http://dx.doi.org/10.1182/blood-2015-01-624536DOI Listing
May 2015

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

N Engl J Med 2015 04;372(17):1670-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1502524DOI Listing
April 2015

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

Am J Hematol 2015 Jan;90(1):82-3

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23871DOI Listing
January 2015

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

N Engl J Med 2015 Jan;372(5):426-35

From Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence (A.M.V.), Ospedale di Circolo e Fondazione Macchi, Varese (F. Passamonti), and University of Naples Federico II, Naples (F. Pane) - all in Italy; Hôpital Saint-Louis et Université Paris Diderot, Paris (J.J.K.); Johannes Wesling Clinic, Minden, Germany (M.G.); St. István and St. László Hospital and Semmelweis University, Budapest, Hungary (T.M.); Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia (S.D.); Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.); Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium (P.Z.); Mayo Clinic Cancer Center, Scottsdale, AZ (R.M.); Incyte, Wilmington, DE (S.H., M.M.J., W.G.); Novartis Pharmaceuticals, East Hanover, NJ (J.L., D.H.); Novartis Pharma, Basel, Switzerland (U.P.); and University of Texas M.D. Anderson Cancer Center, Houston (S.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1409002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358820PMC
January 2015

How I treat polycythemia vera.

Blood 2014 Nov 2;124(22):3212-20. Epub 2014 Oct 2.

Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-551929DOI Listing
November 2014